GlobeNewswire·Nov 3, 2025, 11:05 AM ET

Legend Biotech Announces 10 Presentations at the 67th American Society of Hematology (ASH) Annual Meeting

LEGN

Legend Biotech will present two oral and seven poster abstracts on CARVYKTI (ciltacabtagene autoleucel) for multiple myeloma at the 67th ASH Annual Meeting in Orlando from December 6-9, 2025.
The company will also deliver an oral presentation on first-in-human Phase 1 data for Lucar-G39D, an investigational allogeneic anti-CD20/CD19 dual-CAR gamma delta T cell therapy for relapsed or refractory B-cell non-Hodgkin lymphoma.
CARVYKTI is the first BCMA-targeted CAR-T therapy approved for multiple myeloma patients with at least one prior line of therapy, currently commercially available in 14 countries & having treated over 9,000 patients.
Presentations include data on long-term progression-free survival, immune fitness benefits from earlier treatment use, bridging therapy effectiveness, comparative efficacy analyses, quality-adjusted survival outcomes for neurologic events, & real-world management of non-ICANS neurologic events.
CARVYKTI carries a boxed warning for cytokine release syndrome (CRS), neurologic toxicities (including ICANS, parkinsonism, Guillain-Barré syndrome, & myelitis), HLH/MAS, prolonged cytopenias, infections, hypogammaglobulinemia, & secondary hematological malignancies.
In CARTITUDE-4, early mortality was numerically higher in the CARVYKTI arm, with 14% of deaths occurring within 10 months compared to 12% in the control arm.
Clinical trial data reported CRS in 84% of patients (4% Grade 3), neurologic toxicities in 24% (7% Grade 3), & hypogammaglobulinemia in 94% of patients receiving CARVYKTI.
Secondary malignancies, including myelodysplastic syndrome & acute myeloid leukemia, were observed in 5% of patients in clinical studies, with a median time to onset of 447 days.
Legend Biotech is headquartered in the US, employs over 2,800 people, & markets CARVYKTI in collaboration with Johnson & Johnson.